Seroprevalence of anti-SARS-CoV-2 in patients with hepatitis B and C: a pre-vaccination study
This study aims to assess the prevalence of anti-SARS-CoV-2 in hepatitis B and C patients in a pre-vaccination of COVID-19 period. Between March 2020 and January 2021, 199 serum samples from individuals with HBsAg/HBV DNA or anti-HCV/HCV RNA positivity were tested for antibodies (IgM and IgG) against SARS-CoV-2 using Electrochemiluminescent Immunoassay (ECLIA). Among these, 50.3 % (100/199) tested positive for hepatitis C virus infection and 49.7 % (99/199) for hepatitis B virus, confirmed through molecular and serological diagnosis. The anti-SARS-CoV-2 seroprevalence was 24.1 % (48/199) in this population, with 23.23 % (2...
Source: Braz J Infect Dis - April 26, 2024 Category: Infectious Diseases Authors: Lucas Lima da Silva Lia Laura Lewis-Ximenez Monica Magalhaes Figueiredo Vanessa Salete de Paula Livia Melo Villar Source Type: research
Exploring Hepatocellular Carcinoma Risks in Sub-Saharan African and Afro-Surinamese Individuals with Chronic Hepatitis B living in Europe
We read with great interest the article by Lesley A. Patmore et al., published in the Journal of Hepatology, titled “Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe [1].” The study highlights that, among chronic hepatitis B (CHB) patients of Sub-Saharan African and Afro-Surinamese descent residing in Europe, the cumulative incidenc e rates of hepatocellular carcinoma (HCC) over 5 and 10 years are 1% and 2.4%, respectively. (Source: Journal of Hepatology)
Source: Journal of Hepatology - April 26, 2024 Category: Gastroenterology Authors: Mo-Yao Tan, Jun-Hua Su Tags: Letter to the Editor Source Type: research
Inhibition of hepatitis B virus < em > via < /em > selective apoptosis modulation by Chinese patent medicine Liuweiwuling Tablet
CONCLUSION: Preliminary results suggest that LWWL exerts a potent inhibitory effect on wild-type and drug-resistant HBV, potentially involving selective regulation of apoptosis. These findings offer novel insights into the anti-HBV activities of LWWL and present a novel mechanism for the development of anti-HBV medications.PMID:38659485 | PMC:PMC11036500 | DOI:10.3748/wjg.v30.i13.1911 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - April 25, 2024 Category: Gastroenterology Authors: Fei-Lin Ge Yan Yang Lan-Lan Si Yuan-Hua Li Meng-Zhen Cao Jun Wang Zhao-Fang Bai Zhi-Gang Ren Xiao-He Xiao Yan Liu Source Type: research
Inhibition of hepatitis B virus < em > via < /em > selective apoptosis modulation by Chinese patent medicine Liuweiwuling Tablet
CONCLUSION: Preliminary results suggest that LWWL exerts a potent inhibitory effect on wild-type and drug-resistant HBV, potentially involving selective regulation of apoptosis. These findings offer novel insights into the anti-HBV activities of LWWL and present a novel mechanism for the development of anti-HBV medications.PMID:38659485 | PMC:PMC11036500 | DOI:10.3748/wjg.v30.i13.1911 (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - April 25, 2024 Category: Gastroenterology Authors: Fei-Lin Ge Yan Yang Lan-Lan Si Yuan-Hua Li Meng-Zhen Cao Jun Wang Zhao-Fang Bai Zhi-Gang Ren Xiao-He Xiao Yan Liu Source Type: research
Synthesis and evaluation of pentacyclic triterpenoids conjugates as novel HBV entry inhibitors targeting NTCP receptor
In this study, pentacyclic triterpenoids (PTs) including glycyrrhetinic acid (GA), oleanolic acid (OA), ursolic acid (UA) and betulinic acid (BA) were modified via molecular hybridization with podophyllotoxin respectively, and resulted in thirty-two novel conjugates. The anti-HBV activities of conjugates were evaluated in HepG2.2.15 cells. The results showed that 66% of the conjugates exhibited lower toxicity to the host cells and had significant inhibitory effects on the two HBV antigens, especially HBsAg. Notably, the compounds BA-PPT1, BA-PPT3, BA-PPT4, and UA-PPT3 not only inhibited the secretion of HBsAg but also supp...
Source: Bioorganic Chemistry - April 25, 2024 Category: Chemistry Authors: Yixin Chen Meitao Duan Xiangwan Wang Jianling Xu Shuo Tian Xiaotian Xu Ao Duan Ahmed Mahal Yongyan Zhu Quanhong Zhu Source Type: research
Interim analysis of the PARADISE study: benefits of add-on peginterferon- α in NA-treated patients with CHB
This study aimed to investigate whether peginterferon-α (IFN) add-on nucleos(t)ide analogs(NAs) can further reduce hepatocellular carcinoma(HCC) risk compared with NAs monotherapy in NA-treated patients with chronic hepatitis B(CHB). In this multi-center randomized controlled trial "PARADISE study" (NCT05671315), CHB patients with intermediate to high risk of HCC after more than 24-week NAs pretreatment were recruited, randomized to two groups at a ratio of 1:2 and followed up for 240 weeks. NAs group maintained NAs monotherapy, while IFN+NAs group received IFN add-on NAs therapy for 48 weeks, then switched to NAs monothe...
Source: Antiviral Research - April 25, 2024 Category: Virology Authors: Shaowen Jiang Simin Guo Yan Huang Jie Xu Yi Li Yilan Zeng Yuan Guo Lijuan Ouyang Chuanwu Zhu Weifeng Zhao Qin Zhang Qing Guo Haiguang Xin Qing Xie Source Type: research
Inhibition of hepatitis B virus < em > via < /em > selective apoptosis modulation by Chinese patent medicine Liuweiwuling Tablet
CONCLUSION: Preliminary results suggest that LWWL exerts a potent inhibitory effect on wild-type and drug-resistant HBV, potentially involving selective regulation of apoptosis. These findings offer novel insights into the anti-HBV activities of LWWL and present a novel mechanism for the development of anti-HBV medications.PMID:38659485 | PMC:PMC11036500 | DOI:10.3748/wjg.v30.i13.1911 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - April 25, 2024 Category: Gastroenterology Authors: Fei-Lin Ge Yan Yang Lan-Lan Si Yuan-Hua Li Meng-Zhen Cao Jun Wang Zhao-Fang Bai Zhi-Gang Ren Xiao-He Xiao Yan Liu Source Type: research
Inhibition of hepatitis B virus < em > via < /em > selective apoptosis modulation by Chinese patent medicine Liuweiwuling Tablet
CONCLUSION: Preliminary results suggest that LWWL exerts a potent inhibitory effect on wild-type and drug-resistant HBV, potentially involving selective regulation of apoptosis. These findings offer novel insights into the anti-HBV activities of LWWL and present a novel mechanism for the development of anti-HBV medications.PMID:38659485 | PMC:PMC11036500 | DOI:10.3748/wjg.v30.i13.1911 (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - April 25, 2024 Category: Gastroenterology Authors: Fei-Lin Ge Yan Yang Lan-Lan Si Yuan-Hua Li Meng-Zhen Cao Jun Wang Zhao-Fang Bai Zhi-Gang Ren Xiao-He Xiao Yan Liu Source Type: research
Synthesis and evaluation of pentacyclic triterpenoids conjugates as novel HBV entry inhibitors targeting NTCP receptor
In this study, pentacyclic triterpenoids (PTs) including glycyrrhetinic acid (GA), oleanolic acid (OA), ursolic acid (UA) and betulinic acid (BA) were modified via molecular hybridization with podophyllotoxin respectively, and resulted in thirty-two novel conjugates. The anti-HBV activities of conjugates were evaluated in HepG2.2.15 cells. The results showed that 66% of the conjugates exhibited lower toxicity to the host cells and had significant inhibitory effects on the two HBV antigens, especially HBsAg. Notably, the compounds BA-PPT1, BA-PPT3, BA-PPT4, and UA-PPT3 not only inhibited the secretion of HBsAg but also supp...
Source: Bioorganic Chemistry - April 25, 2024 Category: Chemistry Authors: Yixin Chen Meitao Duan Xiangwan Wang Jianling Xu Shuo Tian Xiaotian Xu Ao Duan Ahmed Mahal Yongyan Zhu Quanhong Zhu Source Type: research
Interim analysis of the PARADISE study: benefits of add-on peginterferon- α in NA-treated patients with CHB
This study aimed to investigate whether peginterferon-α (IFN) add-on nucleos(t)ide analogs(NAs) can further reduce hepatocellular carcinoma(HCC) risk compared with NAs monotherapy in NA-treated patients with chronic hepatitis B(CHB). In this multi-center randomized controlled trial "PARADISE study" (NCT05671315), CHB patients with intermediate to high risk of HCC after more than 24-week NAs pretreatment were recruited, randomized to two groups at a ratio of 1:2 and followed up for 240 weeks. NAs group maintained NAs monotherapy, while IFN+NAs group received IFN add-on NAs therapy for 48 weeks, then switched to NAs monothe...
Source: Antiviral Research - April 25, 2024 Category: Virology Authors: Shaowen Jiang Simin Guo Yan Huang Jie Xu Yi Li Yilan Zeng Yuan Guo Lijuan Ouyang Chuanwu Zhu Weifeng Zhao Qin Zhang Qing Guo Haiguang Xin Qing Xie Source Type: research
Inhibition of hepatitis B virus < em > via < /em > selective apoptosis modulation by Chinese patent medicine Liuweiwuling Tablet
CONCLUSION: Preliminary results suggest that LWWL exerts a potent inhibitory effect on wild-type and drug-resistant HBV, potentially involving selective regulation of apoptosis. These findings offer novel insights into the anti-HBV activities of LWWL and present a novel mechanism for the development of anti-HBV medications.PMID:38659485 | PMC:PMC11036500 | DOI:10.3748/wjg.v30.i13.1911 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - April 25, 2024 Category: Gastroenterology Authors: Fei-Lin Ge Yan Yang Lan-Lan Si Yuan-Hua Li Meng-Zhen Cao Jun Wang Zhao-Fang Bai Zhi-Gang Ren Xiao-He Xiao Yan Liu Source Type: research
Inhibition of hepatitis B virus < em > via < /em > selective apoptosis modulation by Chinese patent medicine Liuweiwuling Tablet
CONCLUSION: Preliminary results suggest that LWWL exerts a potent inhibitory effect on wild-type and drug-resistant HBV, potentially involving selective regulation of apoptosis. These findings offer novel insights into the anti-HBV activities of LWWL and present a novel mechanism for the development of anti-HBV medications.PMID:38659485 | PMC:PMC11036500 | DOI:10.3748/wjg.v30.i13.1911 (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - April 25, 2024 Category: Gastroenterology Authors: Fei-Lin Ge Yan Yang Lan-Lan Si Yuan-Hua Li Meng-Zhen Cao Jun Wang Zhao-Fang Bai Zhi-Gang Ren Xiao-He Xiao Yan Liu Source Type: research
Interim analysis of the PARADISE study: Benefits of add-on peginterferon- α in NA-treated patients with CHB
This study aimed to investigate whether peginterferon-α (IFN) add-on nucleos(t)ide analogs(NAs) can further reduce hepatocellular carcinoma(HCC) risk compared with NAs monotherapy in NA-treated patients with chronic hepatitis B(CHB). In this multi-center randomized controlled trial "PARADISE study" (NCT05671315), CHB patients with intermediate to high risk of HCC after more than 24-week NAs pretreatment were recruited, randomized to two groups at a ratio of 1:2 and followed up for 240 weeks. NAs group maintained NAs monotherapy, while IFN + NAs group received IFN add-on NAs therapy for 48 weeks, then switched to NAs monot...
Source: Antiviral Research - April 25, 2024 Category: Virology Authors: Shaowen Jiang Simin Guo Yan Huang Jie Xu Yi Li Yilan Zeng Yuan Guo Lijuan Ouyang Chuanwu Zhu Weifeng Zhao Qin Zhang Qing Guo Haiguang Xin Qing Xie Source Type: research
Inhibition of hepatitis B virus < em > via < /em > selective apoptosis modulation by Chinese patent medicine Liuweiwuling Tablet
CONCLUSION: Preliminary results suggest that LWWL exerts a potent inhibitory effect on wild-type and drug-resistant HBV, potentially involving selective regulation of apoptosis. These findings offer novel insights into the anti-HBV activities of LWWL and present a novel mechanism for the development of anti-HBV medications.PMID:38659485 | PMC:PMC11036500 | DOI:10.3748/wjg.v30.i13.1911 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - April 25, 2024 Category: Gastroenterology Authors: Fei-Lin Ge Yan Yang Lan-Lan Si Yuan-Hua Li Meng-Zhen Cao Jun Wang Zhao-Fang Bai Zhi-Gang Ren Xiao-He Xiao Yan Liu Source Type: research
Inhibition of hepatitis B virus < em > via < /em > selective apoptosis modulation by Chinese patent medicine Liuweiwuling Tablet
CONCLUSION: Preliminary results suggest that LWWL exerts a potent inhibitory effect on wild-type and drug-resistant HBV, potentially involving selective regulation of apoptosis. These findings offer novel insights into the anti-HBV activities of LWWL and present a novel mechanism for the development of anti-HBV medications.PMID:38659485 | PMC:PMC11036500 | DOI:10.3748/wjg.v30.i13.1911 (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - April 25, 2024 Category: Gastroenterology Authors: Fei-Lin Ge Yan Yang Lan-Lan Si Yuan-Hua Li Meng-Zhen Cao Jun Wang Zhao-Fang Bai Zhi-Gang Ren Xiao-He Xiao Yan Liu Source Type: research
